Open Nav

Kenneth LaMontagne, MBA, PhD

Vice President, Research TAP (Therapy Acceleration Program)

The Leukemia & Lymphoma Society

Ken has been leading the Therapy Acceleration Program (TAP) at the Leukemia & Lymphoma Society. Ken is responsible for the venture philanthropy arm of LLS; investing in promising blood cancer assets from academia and biotech. Currently the TAP portfolio has 20 assets and Ken has been part of recent deals including early programs from biotech. TAP is part of Research at LLS and its purpose is to fund projects related to therapies or diagnostics that have the potential to change the standard of care for patients with blood cancers. Within its 10 year history, TAP has two successful FDA approved assets: Celator Pharmaceuticals (now Jazz Pharmaceuticals) with Vyxeos for AML and Kite Pharma (now Gilead Sciences) with Yescarta for NHL.

This speaker's sessions: